All three tenses have at least two readings, so the archetype blend applies as printed.
Of the nine metrics, 8 read as filed from the record and 1 is an SI estimate, each with its reasoning, its confidence and what would change it on its card.
What did they actually do?
Has it survived what it has been through?
6 warning events since 2017; the latest 2023-10-18.
From the record
Abeona Therapeutics Inc.'s filings since 2017 show 6 warning events of 2 kinds: a notice about its exchange listing (8-K item 3.01, 5 times, the latest 2022-05-19); an auditor change (8-K item 4.01, the latest 2023-10-18) (its current reports).
A production reading, recomputed from the filings on every data build, read from EDGAR Nov 13, 2026.
What has it actually done, year after year?
+27.4% a year over 7 filed years; profitable in 1 of 9.
From the record
Abeona Therapeutics Inc.'s 7 filed years say what it did: revenue went from $837 thousand in fiscal 2017 to $6 million in fiscal 2025, up 27.4% a year; it rose in 4 of 6 years; the deepest fall was 86% from fiscal 2020 to fiscal 2022; net income was positive in 1 of 9 of those years (its annual reports).
What it rests on
A production reading, recomputed from the filings on every data build, read from EDGAR Nov 13, 2026.
How has it treated the people who own it?
SI estimate 2.3/10, confidence 35 of 100 (one part).
SI estimate Inferred, not read as filed
From the record
SI estimate, not a filed reading: Abeona Therapeutics Inc.'s shareholder treatment is put at 2.3 of 10 with a confidence of 35 of 100, because read from one part only, the share count over the years, which ranks in the bottom 23% of 464 in its family; fewer than two of the parts can be read: the share count over the years, and the cash returned against a positive operating cash flow or net income. A filing that carries the missing parts replaces this estimate with the filed reading.
What are they doing right now?
Is it financially healthy right now?
ROE 45%: 45¢ of profit per shareholder dollar. Leverage 27%: owes 27¢ per asset dollar.
From the record
Return on equity: in the fiscal year ended 2025-12-31, Abeona Therapeutics Inc. earned about 45 cents of profit for every dollar of shareholders' money, and gross profitability: its products earned about 2 cents per dollar of everything the company owns (revenue less the cost of revenue). Leverage: it owed about 27 cents per dollar of assets, and net share issuance: its share count grew 29.0% over the year (the filed statements).
What it rests on
A production reading, recomputed from the filings on every data build, read from EDGAR Nov 13, 2026.
How strong is its position in its industry?
top 35% of 315 in its family; net margin 1223.1%.
From the record
Abeona Therapeutics Inc.'s standing among 315 graded names in its industry family: revenue of $6 million in fiscal 2025 ranks in the bottom 35% by size; a net margin of 1223.1% ranks in the top 1%; revenue growth of 18% a year over the last 3 filed years ranks in the top 39% (its annual reports).
What it rests on
A production reading, recomputed from the filings on every data build, read from EDGAR Nov 13, 2026.
What are the people in charge doing?
top 49% of 315 in its family for leadership; chief executive since 2021.
From the record
Abeona Therapeutics Inc.'s leadership, from its insiders' filings and its current reports: the chief executive on the record is Seshadri, Vishwas (Chief Executive Officer, as filed), filing under that title since 2021-10-18, 5.1 years (bottom 49% of its family); the 13 officers and directors filing in the last fifteen months have been on the record a median of 5.5 years (bottom 46%); 5 officer or director changes were reported on Form 8-K since 2023-11-13, against the 13 people in charge now (top 41%; fewer changes for each person reads higher) (the Form 4 record, its Form 8-K reports). Years count from a person's first filing in the SEC's data sets, which begin in 2006, so each is a floor.
What it rests on
A production reading, recomputed from the filings on every data build, read from EDGAR Nov 13, 2026.
What are they set up to do next?
How much room does it have to grow?
bottom 49% of 273 in its family for room to expand.
From the record
Abeona Therapeutics Inc.'s room to grow, from the newest filed statements (fiscal 2025): cash of $78 million against debt of $20 million leaves 26.6% of its assets as net cash, bottom 49% of its family; cash from operations less capital spending is -1448.5% of revenue (bottom 20%); a gross margin of 73.7% (top 44%); research spending of 460.7% of revenue (top 30%) (its annual report).
What it rests on
A production reading, recomputed from the filings on every data build, read from EDGAR Nov 13, 2026.
What could actually drive growth from here?
top 39% of 306 in its family for growth drivers.
From the record
Abeona Therapeutics Inc.'s growth drivers, from the filed years to fiscal 2025: revenue grew 18% a year over the last three filed years against 27.4% over all 7, slowing (bottom 35% of its family); the newest year grew 28.9% (top 33%); research spending grew -2.5% a year (bottom 43%); capital spending grew 294.3% a year (top 1%) (its annual reports). Abeona Therapeutics Inc. reported 2 product lines in fiscal 2025: License at $3 million (58%), Product at $2 million (42%) (its annual report).
What it rests on
A production reading, recomputed from the filings on every data build, read from EDGAR Nov 13, 2026.
Did its newest year beat what its own record pointed to?
top 11% of 233 in its family for expectations against reality.
From the record
Abeona Therapeutics Inc.'s newest year against its own record: revenue of $6 million in fiscal 2025 came in 53.9% above the $4 million its prior three years' pace pointed to (top 18% of its family); net income of $71 million against a prior three-year average of $60 million (top 6%); a net margin of more than its whole revenue against losses larger than its revenue before (top 10%) (its annual reports).
What it rests on
A production reading, recomputed from the filings on every data build, read from EDGAR Nov 13, 2026.
The grade is the company against its own industry, from its filings. It is not a view on the share price. How the grade is made